{"id":"intermediate-metabolisers","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3898295","moleculeType":"Small molecule","molecularWeight":"336.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This term refers to a patient phenotype rather than a therapeutic agent. Intermediate metabolisers have heterozygous or reduced-function variants in drug-metabolizing enzymes (commonly CYP2D6, CYP2C19, or others), resulting in slower drug metabolism than extensive metabolisers but faster than poor metabolisers. This classification is used for dose optimization and safety monitoring of drugs dependent on these pathways.","oneSentence":"Intermediate metabolisers is not a drug but a pharmacogenetic classification describing individuals with moderate capacity to metabolize certain medications via cytochrome P450 enzymes.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:49:19.627Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04619927","phase":"PHASE4","title":"Genotype-guided Strategy for Antithrombotic Treatment in Peripheral Arterial Disease.","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2021-03-01","conditions":"Peripheral Arterial Disease","enrollment":2276},{"nctId":"NCT04198948","phase":"PHASE1","title":"Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers","status":"COMPLETED","sponsor":"University of Sarajevo","startDate":"2019-03-04","conditions":"Diabetes Mellitus, Type 2","enrollment":15},{"nctId":"NCT03869086","phase":"NA","title":"Metabolism of Anthocyanins and Heart Health","status":"TERMINATED","sponsor":"University of East Anglia","startDate":"2019-06-04","conditions":"Healthy","enrollment":49},{"nctId":"NCT01994941","phase":"PHASE4","title":"Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2013-08","conditions":"Acute Coronary Syndrome","enrollment":133},{"nctId":"NCT00713765","phase":"PHASE1","title":"Pharmacokinetic Interaction Between AZD3480 and Donepezil","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2008-12","conditions":"Alzheimer's Disease","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":45,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Intermediate metabolisers","genericName":"Intermediate metabolisers","companyName":"Radboud University Medical Center","companyId":"radboud-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}